CD226 Antikörper (AA 19-254)
Kurzübersicht für CD226 Antikörper (AA 19-254) (ABIN7976558)
Target
Alle CD226 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Bindungsspezifität
- AA 19-254
-
Verwendungszweck
- Anti-CD226 Antibody
-
Kreuzreaktivität (Details)
- No cross-reactivity with other proteins
-
Produktmerkmale
- Anti-CD226 Antibody. Tested in ELISA, Flow Cytometry, WB applications. This antibody reacts with Human, Mouse.
-
Aufreinigung
- Immunogen affinity purified.
-
Immunogen
- E.coli-derived human CD226 recombinant protein (Position: E19-A254).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Western blot, 0.25-0.5 μg/mL, Human, Mouse Flow Cytometry (Fixed), 1-3 μg/1x106 cells, Human ELISA, 0.1-0.5 μg/mL, -
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Konzentration
- 500 μg/mL
-
Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
-
At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing. -
Haltbarkeit
- 12 months
-
-
- CD226
-
Andere Bezeichnung
- CD226
-
Hintergrund
-
Background: DNAM 1, also known as CD226, is a receptor expressed by peripheral blood T lymphocytes that is involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T lymphocytes. DNAM 1 is broadly expressed on T cells, NK cells, platelets, monocytes and a subset of B cells. DNAM-1 is also expressed by a subset of CD3 positive thymocytes. This antibody is reported to inhibit T- and NK cell mediated cytotoxicity against tumour cell targets and to block TNF alpha and IFN gamma secretion by alloantigen-specific T-cells.
Gene Full Name: CD226 Molecule
-
Molekulargewicht
- 70 kDa
-
Gen-ID
- 10666
-
UniProt
- Q15762
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-